Ajay Kumar is an accomplished professional with experience in various Life science organizations including Biotechs/Pharma, Science based CROs, Large Chemical conglomerate. Over the period of many years he has managed multiple projects from the Drug Discovery to Early and mid-stage clinical trials. Some of the important projects include Paclitaxel “Taxol” and its analogs. He has also managed other INDs, aNDAs and CTA/CTX for iv and oral drugs. The different stages of projects and programs managed have varied from early discovery all the way to late Phase II (proof of concept) clinical trial.

Ajay also has the finance and business management education and training for creating and managing budgets, cost control, business plans, corporate finance and corporate structure. Over the past few years he has been successful in the areas of negotiation, in-/out-licensing and contracting with the ability to package the license asset in a way so as to attract investors, but making sure that the scientific and medicinal goals are met or exceeded in those assets. Very experienced in doing financial valuations (intrinsic or extrinsic) of various projects or firms using current financial tools. This valuations has been key in creating business plans for out-licensing or looking at value for in-licensing. Ajay has a number of years experience in Merger and Acquisitions and was the lead executive in the sale of one his companies to a German holding corp.  In addition over the last 6 years Ajay has managed over 100 Due-Diligence efforts of varying complexity where teams have been assembled with scientific/technical, market analysis, Intellectual property and business/corporate/legal members.

Ajay Kumar has a PhD in Life Sciences and then an MBA in finance from Rutgers University.